Physician profile
Obinna O Adigweme
NPI 1356636591
$84,690.58
in general payments reported to CMS, 2019-2025
33 companies · $3,302 in 2025
The $3,302 reported for 2025 was more than what 78% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,447 · 2020: $5,447 · 2021: $11K · 2022: $15K · 2023: $30K · 2024: $14K · 2025: $3,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $36K · Food and Beverage: $7,933 · Travel and Lodging: $3,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $35,975.79 |
| Food and Beverage | $7,932.60 |
| Travel and Lodging | $3,435.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $23,397.21 | 2019-2025 | Velys, Actis, Kincise |
| Omnilife Science, INC | $12,987.59 | 2021-2024 | Omnibotics 3.0, Various Products |
| Depuy Synthes Products, INC. | $11,902.83 | 2022-2024 | Velys, Kincise, Actis |
| Zimmer Biomet Holdings, INC. | $8,334.88 | 2022-2025 | Persona, Mymobility Platform, Oxford |
| Arthrex, INC. | $7,605.94 | 2019-2025 | Arthrex |
| Stryker Corporation | $6,568.57 | 2019-2025 | Mako, Gamma, Infinity |
| Reel Surgical, INC. | $5,573.70 | 2020-2024 | |
| Depuy Synthes Sales INC. | $3,038.93 | 2019-2025 | Velys, Actis, Attune |
| Smith+Nephew, INC. | $1,385.61 | 2019-2022 | |
| Conformis, INC. | $593.30 | 2020-2021 | |
| Kerecis Limited | $477.15 | 2021 | |
| Medtronic, INC. | $404.57 | 2021-2023 | Intellis Adaptivestim |
| Abbott Laboratories | $370.64 | 2022-2023 | Proclaim |
| Treace Medical Concepts, INC. | $300.42 | 2021 | |
| Medacta USA, INC. | $244.31 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthalign INC | $234.08 | 2019-2022 | |
| Integra Lifesciences Corporation | $159.88 | 2024-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Davol INC. | $159.67 | 2024-2025 | Arista, Arista Ah Flexitip |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| Bard Peripheral Vascular, INC. | $108.79 | 2021 | |
| Uoc USA INC | $108.75 | 2025 | Uts, Conformity, U-Mii, U2 Revision Stem, Psa, Ustar, U2 Knee |
| Convatec INC. | $107.19 | 2019 | |
| Next Science LLC | $104.42 | 2024 | Xperience, Blastx, Surgx |
| Paladin Technology Solutions | $103.34 | 2024 | |
| Novosource, LLC | $69.23 | 2023 | |
| Ferring Pharmaceuticals INC. | $47.19 | 2019-2020 | |
| Medtronic USA, INC. | $47.14 | 2020 | |
| Heron Therapeutics, INC. | $36.10 | 2025 | Zynrelef |
| Polynovo North America LLC | $27.19 | 2025 | Novosorb Btm |
| Csl Behring | $21.68 | 2019 | |
| Horizon Therapeutics Plc | $18.97 | 2020 | |
| Guard Medical INC. | $15.78 | 2025 | Npseal |
| Ethicon US, LLC | $10.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Obinna Adigweme listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.